Vilin Bio Med
- P/E
- 24.16
Key Fundamentals
SMEPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · TTM
- ROCE
- 10.80%
- Debt to Equity
- 0.01
- EPS (TTM)
- ₹2.20
- Book Value
- ₹18.60
- Market Cap
- —
- P/E (TTM)
- 24.16
- P/B
- 2.86
- ROE
- 7.51%
- Dividend Yield
- 0.00%
- EBITDA
- ₹3.20 Cr
- 52W High
- ₹60.95
- 52W Low
- ₹18.95
- Volume
- 0
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Vilin Bio Med (this company) | ₹53.15 | 24.16 | ₹81 Cr | 2.86 | 0.00% | 7.51% | 10.80% | ₹8 Cr | ₹1 Cr |
| Median 8 companies | ₹1,587.70 | 37.20 | ₹1,25,337 Cr | 4.57 | 0.44% | 16.25% | 16.65% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 58
- Good
- Returns, margins, earnings quality 22% weight
- Valuation
- 35
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 99
- Strong
- Sales & profit trajectory 9% weight
- Financial Health
- 75
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 79
- Strong
- Trend strength, vol-adjusted 12% weight
- Ownership
- 53
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Company has reduced debt.
- Company is almost debt free.
Weaknesses
4- Stock is trading at 2.80 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -2.92%
- Company has a low return on equity of 3.53% over last 3 years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 3 | 6 | 10 |
| Oscillators | Bearish | 3 | 6 | 0 |
| Moving Averages | Strong Bullish | 0 | 0 | 10 |
Oscillators
Bearish
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 51.96
- Neutral
- MACD (12,26,9)
- −0.02
- Bearish
- SMA (50)
- 51.50
- Bullish
- SMA (200)
- 39.42
- Bullish
As of
Growth Rate
From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.
Revenue
| 5Y | +29.64% |
|---|---|
| 3Y | +50.85% |
| 1Y | +185.35% |
Net profit
| 5Y | +74.29% |
|---|---|
| 3Y | +15.58% |
| 1Y | +777.27% |
Operating cash flow
| 5Y | Turned positive |
|---|---|
| 3Y | Turned positive |
| 1Y | +233.33% |
Operating margin· change in pp
| 5Y | +0.12 pp |
|---|---|
| 3Y | −13.39 pp |
| 1Y | +2.24 pp |
Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.
Revenue by year
| Mar 2020 | ₹16.62 Cr |
|---|---|
| Mar 2021 | ₹11.54 Cr |
| Mar 2022 | ₹11.21 Cr |
| Mar 2023 | ₹12.31 Cr |
| Mar 2024 | ₹15.80 Cr |
| Mar 2025 | ₹14.81 Cr |
| Mar 2026 | ₹42.26 Cr |
Net profit by year
| Mar 2020 | ₹0.16 Cr |
|---|---|
| Mar 2021 | ₹0.12 Cr |
| Mar 2022 | ₹0.03 Cr |
| Mar 2023 | ₹1.25 Cr |
| Mar 2024 | ₹0.16 Cr |
| Mar 2025 | ₹0.22 Cr |
| Mar 2026 | ₹1.93 Cr |
Half-yearly Results
₹ Cr| Particulars | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 4.95 | 4.1 | 8.21 | 7.65 | 8.16 | 4.49 | 10.32 | 9.66 | 32.6 |
| Expenses | 4.56 | 2.99 | 6.74 | 6.26 | 8.73 | 4.07 | 9.95 | 9.32 | 29.74 |
| Operating Profit | 0.39 | 1.11 | 1.47 | 1.39 | −0.57 | 0.42 | 0.37 | 0.34 | 2.86 |
| OPM % | 7.88% | 27.07% | 17.9% | 18.17% | −6.99% | 9.35% | 3.59% | 3.52% | 8.77% |
| Other Income | 0 | 0 | 0.02 | 0.11 | 0.22 | 0.22 | 0.25 | 0 | 0 |
| Interest | 0.25 | 0.32 | 0.33 | 0.38 | 0.41 | 0.41 | 0.44 | 0.07 | 0 |
| Depreciation | 0.11 | 0.08 | 0.08 | 0.08 | 0.05 | 0.07 | 0.03 | 0.07 | 0.21 |
| PBT | 0.03 | 0.71 | 1.08 | 1.04 | −0.81 | 0.16 | 0.15 | 0.2 | 2.65 |
| Tax % | 33.33% | 21.13% | 35.19% | 25.96% | −25.93% | 18.75% | 33.33% | 25% | 32.83% |
| Net Profit | 0.02 | 0.55 | 0.69 | 0.77 | −0.61 | 0.12 | 0.1 | 0.15 | 1.78 |
| EPS (₹) | 0.06 | 1.67 | 0.69 | 0.55 | −0.44 | 0.09 | 0.07 | 0.11 | 1.17 |
Profit & Loss
₹ Cr| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 16.62 | 11.54 | 11.21 | 12.31 | 15.8 | 14.81 | 42.26 |
| Expenses | 15.71 | 10.68 | 10.44 | 9.73 | 14.97 | 14.02 | 39.06 |
| Operating Profit | 0.91 | 0.86 | 0.77 | 2.58 | 0.83 | 0.79 | 3.2 |
| OPM % | 5.48% | 7.45% | 6.87% | 20.96% | 5.25% | 5.33% | 7.57% |
| Other Income | 0.01 | 0 | 0 | 0.02 | 0.32 | 0.47 | 0 |
| Interest | 0.41 | 0.44 | 0.51 | 0.65 | 0.79 | 0.85 | 0.07 |
| Depreciation | 0.31 | 0.26 | 0.22 | 0.17 | 0.13 | 0.1 | 0.28 |
| PBT | 0.2 | 0.16 | 0.04 | 1.78 | 0.23 | 0.31 | 2.85 |
| Tax % | 20% | 25% | 25% | 30.34% | 26.09% | 25.81% | 31.93% |
| Net Profit | 0.16 | 0.12 | 0.03 | 1.25 | 0.16 | 0.22 | 1.93 |
| EPS (₹) | 0.48 | 0.36 | 0.09 | 1.26 | 0.11 | 0.16 | 1.27 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
₹ Cr| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 3.3 | 3.3 | 3.3 | 9.95 | 13.95 | 13.95 | 15.25 |
| Reserves | 3.94 | 4.06 | 4.1 | 0.73 | 8.89 | 9.11 | 13.12 |
| Borrowings | 4.53 | 5.52 | 5.3 | 4.93 | 6.83 | 2.57 | 0.21 |
| Other Liabilities | 2.24 | 1.01 | 0.86 | 2.07 | 2.73 | 2.15 | 6.36 |
| Total Liabilities | 14.01 | 13.89 | 13.56 | 17.68 | 32.4 | 27.78 | 34.94 |
| Fixed Assets | 2.13 | 1.87 | 1.65 | 1.51 | 1.38 | 1.28 | 2.87 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 1.57 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 11.88 | 12.02 | 11.91 | 16.17 | 31.02 | 24.93 | 32.07 |
| Total Assets | 14.01 | 13.89 | 13.56 | 17.68 | 32.4 | 27.78 | 34.94 |
Cash Flow
₹ Cr| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating | −1.46 | −1 | 0.21 | −1.66 | −7.42 | 0.21 | 0.7 |
| Investing | −0.02 | 0 | 0 | −0.03 | 0.32 | −1.11 | −0.3 |
| Financing | 1.51 | 0.98 | −0.22 | 1.68 | 8.87 | −5.1 | 1.01 |
| Net Cash Flow | 0.03 | −0.02 | −0.01 | 0 | 1.77 | −5.99 | 1.41 |
| Free Cash Flow | −1.48 | −1 | 0.21 | −1.69 | −7.42 | −1.36 | 0.4 |
| CFO/OP | −156 | −112 | 29 | −43 | −888 | 35 | 49 |
Ratios
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 160 | 242 | 254 | 166 | 131 | 211 | 138 |
| Inventory Days | 56.13 | 83.17 | 93.82 | 44.74 | 125 | 120 | 70.03 |
| Days Payable | 49.48 | 33.11 | 26.34 | 60.49 | 54.71 | 39.02 | 32.59 |
| Cash Conversion Cycle | 166 | 292 | 321 | 150 | 202 | 291 | 175 |
| Working Capital Days | 111 | 204 | 212 | 45.07 | 76.23 | 375 | 168 |
| ROCE % | — | 4.87% | 4.3% | 17.17% | 4.51% | 4.2% | 10.77% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Vilin Bio Med insights
57 extracted metrics across FY20–FY26.
Documents
- 28 Sep 2026
- 16 Sep 2026
- 15 Sep 2026
- 15 Sep 2026
Frequently Asked Questions about Vilin Bio Med
What does Vilin Bio Med Ltd do?
Where is Vilin Bio Med Ltd (VILINBIO) listed?
Which sector does Vilin Bio Med Ltd belong to?
What is the PE ratio of Vilin Bio Med Ltd?
What is the 52-week high and low of Vilin Bio Med Ltd?
What is the Return on Equity (ROE) of Vilin Bio Med Ltd?
Company Information
Incorporated in 2005, Vilin Bio Med Ltd is in the business of manufacturing and selling of pharmaceutical products
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/VILINBIO.md for Vilin Bio Med Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.